Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 254604101 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
FMR LLC
13G/A
|
12.8% |
8/6/2026
Event 6/30/2026
|
||
| FMR LLC | 12.8% | |||
| Abigail P. Johnson | 12.8% | |||
|
AI Dmi LLC
13D/A
|
8.0% |
10/22/2025
Event 10/20/2025
|
||
| AI Dmi LLC | 8.0% | |||
| Access Industries Holdings LLC | 8.0% | |||
| Access Industries Management, LLC | 8.0% | |||
| Len Blavatnik | 8.0% | |||
|
RA Capital Management, L.P.
13G
|
5.9% |
1/7/2026
Event 12/30/2025
|
||
| RA Capital Management, L.P. | 5.9% | |||
| Peter Kolchinsky | 5.9% | |||
| Rajeev Shah | 5.9% | |||
| RA Capital Healthcare Fund, L.P. | 5.9% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (6) | ||||
|
Orbimed Advisors LLC
13D/A
|
4.5% |
3/12/2025
Event 3/10/2025
|
||
| Orbimed Advisors LLC | 4.5% | |||
| Orbimed Capital GP VI LLC | 1.5% | |||
| OrbiMed Capital GP VIII LLC | 2.4% | |||
| OrbiMed Genesis GP LLC | 0.6% | |||
|
Wellington Management Group LLP
13G/A
|
4.1% |
8/12/2025
Event 6/30/2025
|
||
| Wellington Management Group LLP | 4.1% | |||
| Wellington Group Holdings LLP | 4.1% | |||
| Wellington Investment Advisors Holdings LLP | 4.1% | |||
|
Paradigm Biocapital Advisors LP
13G/A
|
3.5% |
5/15/2025
Event 3/31/2025
|
||
| Paradigm BioCapital Advisors LP | 3.5% | |||
| Paradigm BioCapital Advisors GP LLC | 3.5% | |||
| Senai Asefaw, M.D. | 3.5% | |||
| Paradigm BioCapital International Fund Ltd. | 3.1% | |||
| Bain Capital Life Sciences Opportunities III, LP 13G/A | 3.3% |
2/14/2025
Event 12/31/2024
|
||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
|
3.0% |
8/14/2025
Event 6/30/2025
|
||
| Frazier Life Sciences Public Fund, L.P. | 3.0% | |||
| FHMLSP, L.P. | 3.0% | |||
| FHMLSP, L.L.C. | 3.0% | |||
| Frazier Life Sciences Public Overage Fund, L.P. | 0.9% | |||
| FHMLSP Overage, L.P. | 0.9% | |||
| FHMLSP Overage, L.L.C. | 0.9% | |||
| Frazier Life Sciences X, L.P. | 0.2% | |||
| FHMLS X, L.P. | 0.2% | |||
| FHMLS X, L.L.C. | 0.2% | |||
| Frazier Life Sciences XI, L.P. | 0.8% | |||
| FHMLS XI, L.P. | 0.8% | |||
| FHMLS XI, L.L.C. | 0.8% | |||
| James N. Topper | 0.2% | |||
| Patrick J. Heron | 0.2% | |||
| Albert Cha | 0% | |||
| James Brush | 0% | |||
| Daniel Estes | 0% | |||
|
Atlas Venture Fund X, L.P.
13D/A
|
2.2% |
12/17/2025
Event 12/12/2025
|
||
| Atlas Venture Fund X, L.P. | 2.2% | |||
| Atlas Venture Associates X, L.P. | 2.2% | |||
| Atlas Venture Associates X, LLC | 2.2% | |||
| Atlas Venture Fund XII, L.P. | 0% | |||
| Atlas Venture Associates XII, L.P. | 0% | |||
| Atlas Venture Associates XII, LLC | 0% | |||
| Atlas Venture Opportunity Fund I, L.P. | 0.9% | |||
| Atlas Venture Associates Opportunity I, L.P. | 0.9% | |||
| Atlas Venture Associates Opportunity I, LLC | 0.9% | |||
| Atlas Venture Opportunity Fund II, L.P. | 0.9% | |||
| Atlas Venture Associates Opportunity II, LP | 0.9% | |||
| Atlas Venture Associates Opportunity II, LLC | 0.9% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 445 | $29.1 k |
| 2026 Q2 | 234 | 46.0 M | $3.20 B |
| 2026 Q1 | 212 | 41.9 M | $2.67 B |
| 2025 Q4 | 206 | 38.3 M | $3.04 B |
| 2025 Q3 | 178 | 35.2 M | $2.32 B |
| 2025 Q2 | 157 | 34.1 M | $1.81 B |
| 2025 Q1 | 165 | 33.2 M | $1.65 B |
| 2024 Q4 | 161 | 26.6 M | $1.68 B |
| 2024 Q3 | 140 | 27.5 M | $1.35 B |
| 2024 Q2 | 131 | 28.8 M | $1.30 B |
| 2024 Q1 | 158 | 22.7 M | $1.41 B |
| 2023 Q4 | 122 | 20.4 M | $1.18 B |
| 2023 Q3 | 102 | 19.9 M | $936 M |
| 2023 Q2 | 92 | 19.1 M | $849 M |
| 2023 Q1 | 46 | 14.6 M | $310 M |
| 2022 Q4 | 38 | 11.4 M | $216 M |